You are here: Industry Insights > neuropathic pain

News List

Neuropathic pain market to reach $25.2 billon by 2027: GlobalData expresspharma
May 31, 2021
The neuropathic pain market is the most valuable segment within the pain indications and was valued at $10.8 billion in 2020 globally. It is forecast to reach $25.2 billion by 2027 at a compound annual growth rate (CAGR) of 12.9 per cent.
Peripheral NOP Agonist Addressing Chronic Peripheral Neuropathic Pain Enters Clinical Development americanpharmaceuticalreview
January 06, 2021
Grünenthal announced the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of ...
EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain americanpharmaceuticalreview
April 10, 2020
EicOsis announced the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain.
Averitas Announces sNDA Filing for QUTENZA for Neuropathic Pain americanpharmaceuticalreview
December 20, 2019
Averitas Pharma announced the supplemental New Drug Application (sNDA) for QUTENZA for the treatment of neuropathic pain associated with diabetic peripheral neuropathy ...
Antiepileptics linked to more hospital days in Alzheimer’s patients pharmaceutical-technology
January 23, 2019
A new study by the University of Eastern Finland has found that use of antiepileptic drugs can lead to more hospital days for people living with Alzheimer’s disease....
Vivozon's Non-Opioid Pain Killer Granted FDA Fast Track Designation americanpharmaceuticalreview
November 10, 2018
MMS Holdings announced that the company has successfully assisted Korea-based Vivozon in achieving a Fast Track Designation from the Food and Drug Administration (FDA) for VVZ-149, a non-opioid pain killer.
Selexis, Hoba Therapeutics in Development Pact contractpharma
September 29, 2018
Selexis will use its SUREtechnology Platform to develop a stable, high-performance research cell bank
Selexis SA and Hoba Therapeutics Team Up to Advance Hoba’s Investigational Neuropathic Pain Treatment into the Clinic pharmafocusasia
September 28, 2018
Selexis SA and Hoba Therapeutics announced today that they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 (rhMeteorin) for the treatment of peripheral neuropathic pain.